Response to ‘A temporal paradox in the proposed risk-adjusted surveillance algorithm for metastatic colorectal cancer’

We thank Dr Tian and colleagues1 for their interest in our work titled ‘Risk of disease progression in the first-line therapy of metastatic colorectal cancer to guide disease re-assessments—analysis of eleven trials by AIO and GONO’.2 In their letter, while appreciating the value of investigating a tailored approach to disease monitoring, they raise a concern on the proposed surveillance algorithm.…